NCT06558513View on ClinicalTrials.gov

To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced TumorLymphoma
Interventions
DRUG

XNW5004 tablets

XNW5004 an EZH2 inhibitor, BID, administered in continuous

Trial Locations (1)

Unknown

RECRUITING

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin

Sponsors
All Listed Sponsors
collaborator

Shanghai Dingyue Biotechnology Co., LTD

UNKNOWN

collaborator

Beijing Jiyingjia Medical Laboratory Co.,Ltd.

UNKNOWN

collaborator

Shanghai Jinghan Biological Technology Co., Ltd.

UNKNOWN

lead

Evopoint Biosciences Inc.

INDUSTRY